Hence, we report evidence that any course of treatment, even short in time, might cause quantitative changes in the BCR::ABL1 expression and might also suggest a different impact against CML clones driven by different therapies. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.